Peptide
Sarms LGD-4033

 

Sarms LGD-4033

Selective Androgen Receptor Modulators (SARMs) provide the benefits of traditional anabolic/androgenic agents such as testosterone (including increased muscle mass, fat loss, and bone density) while having lower unwanted side effects characteristic of oral anabolics (aromatization / increased DHT). By stimulating the androgen receptor, SARMs can provide a similar therapeutic outcome to androgen therapy without any increase in androgen levels. SARMs have the potential to take the place of androgens, and therefore exert many of the same positive effects on muscle tissue. SARMs can be administered in an injectable dosage form and are absorbed orally are with no liver toxicity as with most oral steroids. The anabolic effect has been measured to be roughly the same or greater than testosterone. It has also been shown to produce dose-dependent increases in bone mineral density and mechanical strength, decrease body fat and increase lean body mass. LGD-4033 is a relatively new SARM on the market. It can be dosed orally at low doses and has a very strong anabolic effect.

CLINICAL RESEARCH:

The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Me
LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups.
Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone–binding globulin, high-density lipoprotein cholesterol, and triglyceride levels. Follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose-dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation. LGD-4033 was safe, had a favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

Contact us and discover
your new normal.

  • MM slash DD slash YYYY
  • :
  • HOURS OF OPERATION
    Tuesday – Saturday: 10am-6pm
    Sunday – Monday: Closed

Contact us today to
schedule your consult!

Hormone Replacement Therapy

Take the guesswork out of balancing your hormones.

Custom plans at $179/mo

Thyroid Disorder Treatment

Reverse the effects of an age-related thyroid disorder.

Custom plans at $129/mo

Have more questions?

Contact us for a no-obligation consultation. Talk to a VitaHealth expert today.

888-481-8482

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.